Recalcitrant ulcerative pyoderma gangrenosum of the leg responsive to tildrakizumab: A case report
Publication Details
Leow, L. J.,
&
Zubrzycki, N.
(2022).
Recalcitrant ulcerative pyoderma gangrenosum of the leg responsive to tildrakizumab: A case report.
Clinical, Cosmetic and Investigational Dermatology, 15, 1729-1736.
Abstract
Elevated levels of inflammatory mediators—including the interleukin IL-23—are implicated in the pathogenesis of pyoderma gangrenosum (PG), an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, suppurative ulcers and cribriform scarring. Here, we present the first case report of significant response of isolated ulcerative PG with tildrakizumab, a biologic agent directed against the p19 subunit of IL-23, in an elderly woman with extensive treatment-refractory PG on her left leg. Tildrakizumab (100 mg subcutaneously at weeks 0 and 4, then every 8 weeks, and eventually increased in frequency to every 6 weeks), combined with acetic acid soaks each morning and chemical debridement every evening with 3% hydrogen peroxide, resulted in progressive decrease in ulcer size and depth, re-epithelialization, and recovery of sensory perception. This report describes the dramatic clinical response of ulcerative PG on the leg with tildrakizumab.
Keywords
interleukin-23, leg ulcers, pyoderma gangrenosum, biological drug, wound dressing
Link to Publisher Version (URL)
